NEJM publishes Phase 3 data for oveporexton in narcolepsy type 1
Takeda said the New England Journal of Medicine published results from two Phase 3 studies of oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).
Takeda (TSE:4502/NYSE:TAK) said the New England Journal of Medicine published results from two Phase 3 studies of oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1). Oveporexton is described as the first and only medicine to treat the underlying cause of NT1.